Fundraising Fox

Bryn Pharma

Lebanon, US · Founded 2017 · Delaware corporation · 1 known investors

Healthtech

Founders & leadership

JZ
Joshua ZielExecutive
SK
Steven KillmeyerExecutive
JB
James BornemanExecutive
DD
David DworaczykNamed on SEC filing
RS
Rick SchadenNamed on SEC filing

Board

KS
Kate Soper DiazBoard director
AW
Anne WhitakerBoard director
MK
Michael KasetaBoard director
JH
Jeff HartnessBoard director
SH
Steven HartmanBoard director
ML
Michelle LobelBoard director
MR
Marc RapaportBoard director

Investors · 1

RezVen PartnersIrvine

Reported raises · per SEC filings

Form D private placements

$127.4M disclosed across 6 rounds · 2018–2025

▶$4.7MraisedAug 2025 · 105 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Anne WhitakerDirector
  • Michael KasetaDirector
  • Jeff HartnessDirector
  • Steven HartmanDirector
  • Joshua ZielExecutive Officer
  • Michelle LobelDirector
  • Steven KillmeyerExecutive Officer
  • Marc RapaportDirector
  • Lisa LichtDirector
  • Sandra LoreauxDirector
  • James BornemanExecutive Officer
  • Kate Soper DiazDirector
Offering amount
$4.7M
Amount sold
$4.7M
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$26.7MraisedJul 2023 · 105 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David DworaczykExecutive Officer, Director
  • Michael KasetaDirector
  • Michelle LobelExecutive Officer, Director
  • William HumphriesDirector
  • Steve KillmeyerExecutive Officer
  • Sandy LoreauxExecutive Officer, Director
  • Marc RapaportDirector
  • Steven HartmanExecutive Officer, Director
  • Jim BornemanExecutive Officer
  • Kate Soper DiazDirector
  • Anne WhitakerDirector
  • Jeff HartnessDirector
  • Lisa LichtDirector
Offering amount
$30M
Amount sold
$26.7M
First sale
Apr 2023
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$43.5MraisedOct 2022 · 246 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David DworaczykExecutive Officer, Director
  • Steven HartmanExecutive Officer, Director
  • Katherine GrellDirector
  • Robert YanezExecutive Officer
  • Michelle LobelExecutive Officer, Director
Offering amount
$50M
Amount sold
$43.5M
First sale
Jul 2021
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$26MraisedJun 2020 · 127 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Lisa LichtDirector
  • Kate GrellDirector
  • Dale SanderExecutive Officer
  • Marc RapaportDirector
  • Steven HartmanExecutive Officer, Director
  • Stephen BeckmanExecutive Officer
  • David DworaczykExecutive Officer, Director
  • Michelle LobelExecutive Officer, Director
Offering amount
$35M
Amount sold
$26M
First sale
Oct 2019
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17.2MraisedFeb 2019 · 77 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven HartmanExecutive Officer, Director
  • Michelle LobelExecutive Officer, Director
  • Kate GrellDirector
  • Stephen BeckmanExecutive Officer
  • David DworaczykExecutive Officer, Director
Offering amount
$18M
Amount sold
$17.2M
First sale
Feb 2019
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.3MraisedJul 2018 · 72 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Michelle LobelExecutive Officer, Director
  • Steven HartmanExecutive Officer, Director
  • David DworaczykExecutive Officer
  • Rick SchadenDirector
Offering amount
$15M
Amount sold
$9.3M
First sale
Jul 2018
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Bryn Pharma Announces First Participant Dosed in PK/PD Trial with Upgraded Nasal Spray Device, Including First-of-Its-Kind, Two-Doses-in-One Nasal Spray Profilefinance.yahoo.com · Jun 2025Bryn Pharma Raises $11M in Financing - FinSMEsfinsmes.com · Aug 2020Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis - Rezvenrezven.com · Aug 2020Pharmaceutical News Industry Abuzzed About Bryn Pharma Securing US$17.5 Million Funding For New Epinephrine Nasal Spray To Treat Anaphylaxis - Thailand Medical Newsthailandmedical.news · Jan 2020Bryn Pharma Raises $17.5 Million in Financing as it Advances Toward U.S. Application to Market Bidose Epinephrine Nasal Spray for Anaphylaxisprnewswire.com · Oct 2019Bryn Pharma raises $18m for nasal epinephrine device - MassDevicemassdevice.com · Oct 2019

Frequently asked questions

Who are Bryn Pharma's investors?
Bryn Pharma's investors include RezVen Partners.
How much funding has Bryn Pharma raised?
Bryn Pharma has disclosed $127.4M raised across 6 rounds.
Where is Bryn Pharma headquartered?
Bryn Pharma is headquartered in Lebanon, US.